Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

More than a million Brits could be living with undiagnosed diabetes, with early detection being key to managing the condition and maintaining a good quality of life ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

A review of the cases, coupled with the latest research in the field, led the authors to hypothesize that rapid changes ... eye disease in people with Type 2 diabetes. “Because of the association of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

Finding and treating diabetic retinopathy early can reduce the risk of blindness by 95%. Diabetic eye changes are often without symptoms at first. Eye damage can begin during the prediabetes stage and ...

An artificial right heart atrium that could save the lives of children with a rare disease. An AI-powered method to prevent blindness from ...